CYTK 250117 55.00C (CYTK250117C55000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CYTK250117C55000

Watchlist

0.29
-0.11-27.50%

15min DelayClose Jan 10 16:00 ET

0.51High0.24Low

Intraday

5D
Daily

News

Cytokinetics Analyst Ratings
BenzingaJan 10 07:10 ET · Ratings
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireJan 6 16:00 ET
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $62
Moomoo NewsJan 6 06:31 ET · Ratings
Express News | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersJan 3 16:00 ET
Investors Push Cytokinetics (NASDAQ:CYTK) 3.7% Lower This Week, Company's Increasing Losses Might Be to Blame
Simply Wall StDec 31, 2024 10:10 ET
S&P 500 Futures Drop In Premarket Trading; Sportradar Group, Cytokinetics Lead
Dow JonesDec 27, 2024 07:30 ET

Comments

Movers and Shakers

Dec 24, 2024 07:57

Columns Today's Pre-Market Movers and Top Ratings | TIVC, NEUE, X, and More

Morning Movers
Gapping up
$Tivic Health Systems (TIVC.US)$ shares jumped 76% in Tuesday premarket after CEO Jennifer Ernst announced plans for 2025 cash flow initiatives and disease-specific clinical trials for regulatory approvals.
$NeueHealth (NEUE.US)$ stock surged 62% after announcing its agreement to be acquired and taken private by a New Enterprise Associates affiliate in a deal valued at approximately $1.3 billion.
$SEALSQ Corp (LAES.US)$ shares c...

Sean Parker

Nov 19, 2024 02:56

$Cytokinetics (CYTK.US)$
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and ...

Mr Long Term

Aug 13, 2024 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

Rocketier (MAXN)

Jun 11, 2024 07:25

$Cytokinetics (CYTK.US)$ cmonnn I know u can up alot further! 🚀

Rocketier (MAXN)

May 29, 2024 13:05

$Cytokinetics (CYTK.US)$ will there be potential to gain back 100 after the offering?